{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:20:41Z","timestamp":1790716841864,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.medcli.2017.11.030","type":"journal-article","created":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T13:34:47Z","timestamp":1514554487000},"page":"398-402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":152,"title":["Statins: pros and cons"],"prefix":"10.1016","volume":"150","author":[{"given":"Iago","family":"Pinal-Fernandez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Casal-Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Mammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2017.11.030_bib0305","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2183\/pjab.86.484","article-title":"A historical perspective on the discovery of statins","volume":"86","author":"Endo","year":"2010","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"10.1016\/j.medcli.2017.11.030_bib0310","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1073\/pnas.77.7.3957","article-title":"Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent","volume":"77","author":"Alberts","year":"1980","journal-title":"Proc Natl Acad Sci U S A I"},{"key":"10.1016\/j.medcli.2017.11.030_bib0315","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1126\/science.167438","article-title":"Lipid linked sugars in glycoprotein synthesis","volume":"188","author":"Lennarz","year":"1975","journal-title":"Science"},{"key":"10.1016\/j.medcli.2017.11.030_bib0320","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","article-title":"The role of coenzyme Q10 in statin-associated myopathy: a systematic review","volume":"49","author":"Marcoff","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.medcli.2017.11.030_bib0325","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nri1839","article-title":"Statin therapy and autoimmune disease: from protein prenylation to immunomodulation","volume":"6","author":"Greenwood","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.medcli.2017.11.030_bib0330","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart disease and stroke statistics-2017 update: a report from the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.medcli.2017.11.030_bib0335","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1001\/jama.1983.03340130075039","article-title":"Landmark article (JAMA 1912). Clinical features of sudden obstruction of the coronary arteries. By James B. Herrick","volume":"250","author":"Herrick","year":"1983","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2017.11.030_bib0340","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.gheart.2012.12.001","article-title":"Legacy of the framingham heart study: rationale, design, initial findings, and implications","volume":"8","author":"Wong","year":"2013","journal-title":"Glob Heart"},{"key":"10.1016\/j.medcli.2017.11.030_bib0345","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/1047-2797(92)90033-M","article-title":"Lipids and risk of coronary heart disease. The Framingham Study","volume":"2","author":"Castelli","year":"1992","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.medcli.2017.11.030_bib0350","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/bmj.308.6925.367","article-title":"By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?","volume":"308","author":"Law","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.medcli.2017.11.030_bib0355","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/bmj.301.6747.309","article-title":"Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials","volume":"301","author":"Muldoon","year":"1990","journal-title":"BMJ"},{"key":"10.1016\/j.medcli.2017.11.030_bib0360","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2017.11.030_bib0365","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2017.11.030_bib0370","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","article-title":"Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"issue":"Suppl 2","key":"10.1016\/j.medcli.2017.11.030_bib0375","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.medcli.2017.11.030_bib0380","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2017.11.030_bib0385","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1089\/ars.2011.4414","article-title":"Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy","volume":"16","author":"Gupta","year":"2012","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.medcli.2017.11.030_bib0390","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/ATVBAHA.110.210500","article-title":"Induction of endothelial nitric oxide synthase SIRT1, and catalase by statins inhibits endothelial senescence through the Akt pathway","volume":"30","author":"Ota","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.medcli.2017.11.030_bib0395","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.CIR.98.9.839","article-title":"Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators","volume":"98","author":"Ridker","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.medcli.2017.11.030_bib0400","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJM200010193431602","article-title":"Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease","volume":"343","author":"Lindahl","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2017.11.030_bib0405","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0140-6736(05)76154-7","article-title":"Effect of statins on C-reactive protein in patients with coronary artery disease","volume":"353","author":"Strandberg","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2017.11.030_bib0410","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/01.CIR.0000100688.17280.E6","article-title":"Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial","volume":"108","author":"Ridker","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.medcli.2017.11.030_bib0415","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nrd1901","article-title":"Anti-inflammatory effects of statins: clinical evidence and basic mechanisms","volume":"4","author":"Jain","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.medcli.2017.11.030_bib0420","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1160\/TH15-10-0770","article-title":"Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. A systematic review and meta-analysis of randomised controlled trials","volume":"116","author":"Sahebkar","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.medcli.2017.11.030_bib0425","doi-asserted-by":"crossref","first-page":"e0138097","DOI":"10.1371\/journal.pone.0138097","article-title":"Statins increase plasminogen activator inhibitor type 1 gene transcription through a pregnane X receptor regulated element","volume":"10","author":"Stanley","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.medcli.2017.11.030_bib0430","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","article-title":"A randomized trial of rosuvastatin in the prevention of venous thromboembolism","volume":"360","author":"Glynn","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2017.11.030_bib0435","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/j.1742-1241.2010.02439.x","article-title":"Statin use and the prevention of venous thromboembolism: a meta-analysis","volume":"64","author":"Agarwal","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.medcli.2017.11.030_bib0440","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1002\/art.11449","article-title":"Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model","volume":"48","author":"Ferrara","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2017.11.030_bib0445","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1136\/ard.2010.135525","article-title":"Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome","volume":"70","author":"Lopez-Pedrera","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medcli.2017.11.030_bib0450","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ahj.2014.03.019","article-title":"A systematic review of statin-induced muscle problems in clinical trials","volume":"168","author":"Ganga","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.medcli.2017.11.030_bib0455","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/j.1552-4604.1993.tb03948.x","article-title":"Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study","author":"Ghirlanda","year":"1993","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.medcli.2017.11.030_bib0460","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clpt.2005.03.006","article-title":"High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial","volume":"78","author":"Paiva","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.medcli.2017.11.030_bib0465","first-page":"3940","article-title":"The muscle-specific ubiquitin ligase atrogin-1\/MAFbx mediates statin-induced muscle toxicity","volume":"117","author":"Hanai","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.medcli.2017.11.030_bib0470","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.amjmed.2011.08.007","article-title":"Statin use and musculoskeletal pain among adults with and without arthritis","volume":"125","author":"Buettner","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.medcli.2017.11.030_bib0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamainternmed.2013.6184","article-title":"Statins and musculoskeletal conditions, arthropathies, and injuries","volume":"173","author":"Mansi","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.medcli.2017.11.030_bib0480","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2017.11.030_bib0485","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.medcli.2017.11.030_bib0490","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.medcli.2017.11.030_bib0495","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-associated autoimmune myopathy","volume":"374","author":"Mammen","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2017.11.030_bib0500","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2017.11.030_bib0505","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2017.11.030_bib0510","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1002\/art.34673","article-title":"Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Werner","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2017.11.030_bib0515","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/acr.21671","article-title":"Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.medcli.2017.11.030_bib0520","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2017.11.030_bib0525","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/jamacardio.2016.1884","article-title":"Association of lipid fractions with risks for coronary artery disease and diabetes","volume":"1","author":"White","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.medcli.2017.11.030_bib0530","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jama.2015.1206","article-title":"Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus","volume":"313","author":"Besseling","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2017.11.030_bib0535","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","article-title":"Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths","volume":"370","author":"Prospective Studies","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2017.11.030_bib0540","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2017.11.030_bib0545","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2011.07.023","article-title":"Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing","volume":"56","author":"Bjornsson","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2017.11.030_bib0550","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7326\/0003-4819-159-10-201311190-00007","article-title":"Statins and cognitive function: a systematic review","volume":"159","author":"Richardson","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.medcli.2017.11.030_bib0555","doi-asserted-by":"crossref","first-page":"c2197","DOI":"10.1136\/bmj.c2197","article-title":"Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database","volume":"340","author":"Hippisley-Cox","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.medcli.2017.11.030_bib0560","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","article-title":"Cholesterol lowering in intermediate-risk persons without cardiovascular disease","volume":"374","author":"Yusuf","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2017.11.030_bib0565","doi-asserted-by":"crossref","first-page":"976","DOI":"10.5551\/jat.33563","article-title":"Rationale and design of the standard versus intensive statin therapy for hypercholesterolemic patients with diabetic retinopathy (EMPATHY) study: a randomized controlled trial","volume":"23","author":"Ueshima","year":"2016","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.medcli.2017.11.030_bib0570","doi-asserted-by":"crossref","first-page":"e83759","DOI":"10.1371\/journal.pone.0083759","article-title":"Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration","volume":"8","author":"Guymer","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.medcli.2017.11.030_bib0575","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2010.09.082","article-title":"Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50mg\/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)","volume":"57","author":"Hsia","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.medcli.2017.11.030_bib0580","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1681\/ASN.2013090965","article-title":"Effects of lowering LDL cholesterol on progression of kidney disease","volume":"25","author":"Haynes","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.medcli.2017.11.030_bib0585","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJMoa1201735","article-title":"Statin use and reduced cancer-related mortality","volume":"367","author":"Nielsen","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2017.11.030_bib0590","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2017.11.030_bib0595","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2017.11.030_bib0600","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775317309144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775317309144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T05:37:41Z","timestamp":1719725861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775317309144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0025775317309144"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2017.11.030","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statins: pros and cons","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2017.11.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}